Geresu Berhanu, Misganaw Desye, Beyene Yeshiwork
Department of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
BMC Pharmacol Toxicol. 2014 Feb 8;15:4. doi: 10.1186/2050-6511-15-4.
Drug use evaluation is a performance improvement method that focuses on evaluating and improving drug use process to achieve optimal patient outcomes. Drug use evaluation helps in identifying, preventing or resolving actual and potential drug related problems. The objective of the study was to evaluate the use of cotrimoxazole as preventive therapy in people living with HIV/AIDS in Boru Meda Hospital, Northeast Ethiopia.
A retrospective drug use evaluation was conducted on patients' medical history records based on a validated drug use evaluation criteria according to the national guideline. Medical history records of 248 patients were selected using systematic sampling method.
The result showed that 49.6% of the patients were at WHO clinical stage III at the start of cotrimoxazole preventive therapy. In this study, the use of cotrimoxazole preventive therapy was consistent with the guideline in the rationale for indication (97.98%), dose (96.77%), and its use despite the presence of contraindications (91.93%). Problems regarding drug-drug interaction were identified in 49.59% of cases, and 20.97% of patients discontinued cotrimoxazole preventive therapy due to different reasons.
In most patients cotrimoxazole preventive therapy was consistent with the national guideline regarding the rationale for indication, dose, discontinuation and its use in the presence of contraindications.
药物使用评估是一种绩效改进方法，专注于评估和改进药物使用过程以实现最佳患者治疗效果。药物使用评估有助于识别、预防或解决实际和潜在的药物相关问题。本研究的目的是评估在埃塞俄比亚东北部的博罗梅达医院，复方新诺明作为预防疗法在艾滋病毒/艾滋病患者中的使用情况。
根据国家指南，基于经过验证的药物使用评估标准，对患者的病史记录进行回顾性药物使用评估。采用系统抽样方法选取了248例患者的病史记录。
结果显示，在开始复方新诺明预防治疗时，49.6%的患者处于世界卫生组织临床III期。在本研究中，复方新诺明预防治疗在适应证依据（97.98%）、剂量（96.77%）以及存在禁忌证时仍使用（91.93%）方面与指南一致。在49.59%的病例中发现了药物相互作用问题，20.97%的患者因不同原因停止了复方新诺明预防治疗。
在大多数患者中，复方新诺明预防治疗在适应证依据、剂量、停药以及存在禁忌证时的使用方面与国家指南一致。
